SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13D-1(B), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2

(AMENDMENT No.)*

ADVENTRX Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share

(Title of Class of Securities)

00764X202

(CUSIP Number)

January 06, 2011

(Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- o Rule 13d-1(b)
- ⊠ Rule 13d-1(c)
- o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 00764X202				13G	Page 2 of 8 Pages		
1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)						
	TANG CAPITAL PARTNERS, LP						
2	CHECK THE APPROPRIA	ATE BOX II	A MEN	MBER OF A GROUP*	(a) □ (b) ⊠		
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE						
	NUMBER OF	5	SOLE V 0	OTING POWER			
]	BENEFICIALLY OWNED BY EACH REPORTING 2,229, 7 SOLE		SHARED VOTING POWER 2,229,085				
				DISPOSITIVE POWER			
	ERSON WITH	8	SHARE 2,229,08	D DISPOSITIVE POWER 35			
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,229,085						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.42%						
12	TYPE OF REPORTING PERSON PN						

CUSIP No. 00764X202				13G	Page 3 of 8 Pages		
1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)						
	TANG CAPITAL MANAGEMENT, LLC						
2	CHECK THE APPROPRIA	ATE BOX I	F A MEN	MBER OF A GROUP*	(a) □ (b) ⊠		
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE						
	NUMBER OF	5	SOLE V	OTING POWER			
	BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		SHARED VOTING POWER 2,229,085				
E.				DISPOSITIVE POWER			
			D DISPOSITIVE POWER 85				
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,229,085						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.42%						
12	TYPE OF REPORTING PERSON OO						

CUSIP No. 00764X202				13G	Page 4 of 8 Pages		
1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)						
	KEVIN C. TANG						
2	CHECK THE APPROPRIA	ATE BOX II	A MEI	MBER OF A GROUP*	(a) □ (b) ⊠		
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION UNITED STATES						
	NATIONAL OF	5	SOLE V	OTING POWER			
	NUMBER OF SHARES BENEFICIALLY	6	SHARE 2,229,0	D VOTING POWER 85			
OWNED BY EACH REPORTING TO SHEET OF THE PERSON WITH		7	SOLE DISPOSITIVE POWER 0				
	PERSON WITH	8	SHARE 2,229,0	D DISPOSITIVE POWER 85			
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,229,085						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.42%						
12	TYPE OF REPORTING PERSON IN						

Item 1(a). Name of Issuer:

ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

6725 Mesa Ridge Road, Suite 100, San Diego, CA 92121

Item 2(a). Name of Person Filing:

This Statement on Schedule 13G (this "Statement") is filed by Tang Capital Partners, LP ("Tang Capital Partners"); Tang Capital Management, LLC, the general partner of Tang Capital Partners ("Tang Capital Management"); and Kevin C. Tang, the manager of Tang Capital Management.

Item 2(b). Address of Principal Business Office or, if none, Residence:

4401 Eastgate Mall, San Diego, CA 92121

Item 2(c). Citizenship:

Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

Item 2(d). Title of Class of Securities:

Common Stock, \$0.001 par value per share (the "Common Stock")

Item 2(e). CUSIP Number: 00764X202

Item 3. Not applicable.

Item 4. Ownership.

(a) Amount Beneficially Owned:

Tang Capital Partners. Tang Capital Partners is the beneficial owner of 2,229,085 shares of Common Stock and shares voting and dispositive power over such securities with Tang Capital Management and Kevin C. Tang.

Tang Capital Management. Tang Capital Management, as the general partner of Tang Capital Partners, may be deemed to beneficially own the 2,229,085 shares beneficially owned by Tang Capital Partners. Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin C. Tang.

Kevin C. Tang. Kevin C. Tang may be deemed to beneficially own the 2,229,085 shares beneficially owned by Tang Capital Partners. Mr. Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

In addition to the foregoing shares, Tang Capital Partners holds a warrant to purchase 591,250 shares of the Issuer's Common Stock at an exercise price of \$2.75 per share (the "A Warrant"). The A Warrant has an expiration date of January 19, 2012. Tang Capital Partners also holds a warrant to purchase 591,250 shares of the Issuer's Common Stock at an exercise price of \$2.75 per share (the "B Warrant"). The B Warrant has an expiration date of January 11, 2016.

The A Warrant and B Warrant each provide that in no event shall either warrant be exercisable to the extent that the issuance of Common Stock upon the exercise thereof, after taking into account the Common Stock then owned by Tang Capital Partners and its affiliates, would result in the beneficial ownership by Tang Capital Partners and its affiliates of more than 4.99% of the outstanding Common Stock (the "Issuance Limitations"). Tang Capital Partners has the express right, upon sixty-one (61) days written notice to the Issuer, to increase or decrease the Issuance Limitations, provided that in no event can the Issuance Limitations exceed 9.99%. The Issuance Limitations presently remains in effect with respect to each warrant and no shares are currently issuable upon exercise of either warrant. Neither the filing of this Schedule 13G no r any of its contents shall be deemed to constitute an admission by Tang Capital Partners or any other person that it is the beneficial owner of any of the Common Stock underlying each warrant for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and such beneficial ownership is expressly disclaimed.

(b) Percent of Class:

Tang Capital Partners	9.42%
Tang Capital Management	9.42%
Kevin C. Tang	9.42%

- (c) Number of shares as to which such person has:
 - (i) sole power to vote or to direct the vote:

Tang Capital Partners0 sharesTang Capital Management0 sharesKevin C. Tang0 shares

(ii) shared power to vote or to direct the vote:

Tang Capital Partners2,229,085 sharesTang Capital Management2,229,085 sharesKevin C. Tang2,229,085 shares

(iii) sole power to dispose or to direct the disposition of:

Tang Capital Partners0 sharesTang Capital Management0 sharesKevin C. Tang0 shares

(iv) shared power to dispose or to direct the disposition of:

Tang Capital Partners2,229,085 sharesTang Capital Management2,229,085 sharesKevin C. Tang2,229,085 shares

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After	reasonable inquiry and to the best of my knowledge and belief, I certify the	nat the information set forth in this statement is true, complete and correct.
Date:	January 18, 2011	
TAN	G CAPITAL PARTNERS, LP	
By:	Tang Capital Management, LLC, its General Partner	
By:	/s/ Kevin C. Tang Kevin C. Tang, Manager	
TAN	G CAPITAL MANAGEMENT, LLC	
Ву:	/s/ Kevin C. Tang Kevin C. Tang, Manager	
	evin C. Tang	
Kevii	n C. Tang	

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, \$0.001 par value per share, of ADVENTRX Pharmaceuticals, Inc. and further agree to the filing of this agreement as an exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G.

Date: January 18, 2011

TANG CAPITAL PARTNERS, LP

By: Tang Capital Management, LLC

Its: General Partner

By: /s/ Kevin C. Tang

Name: Kevin C. Tang Title: Manager

TANG CAPITAL MANAGEMENT, LLC

By: /s/ Kevin C. Tang

Name: Kevin C. Tang Title: Manager

/s/ Kevin C. Tang

Name: Kevin C. Tang